Try our Advanced Search for more refined results
Life Sciences - February, 2012
219 articles
- Jury Finds Illumina Infringed LadaTech DNA Patent
- Consumer Groups Say Aneurysm Fixer Needs More FDA Tests
- Abbot Targets Amneal In Latest Suit Over Generic Niaspan
- Bill Would Create Registry Of Legit Web Pharmacies
- Indie Pharmacies Claim CMS Rule Stifles Competition
- Current Trends In Health Care Fraud Enforcement
- House Passes Bill To Nix High Court Eminent Domain Ruling
- Ex-Exec Can't Support FCA Claims, Pfizer Tells 1st Circ.
- Dainippon To Pay Up To $2.6B For Cancer Drug Developer
- GOP Lawmakers Lash Out At Employer Contraception Rule
- Bayer, Others Exit Price-Fixing Suit After High Court Win
- Families Toss Bid To Renew J&J, Omnicare Antitrust Suit
- Statins Carry Small Risk Of Diabetes, FDA Warns
- Merck Failed To Probe Diabetes Drugs For Risks: FDA
- Eisai Can't Pry Transcripts From 2003 Aventis Antitrust Suit
- Invalidity Claim To Be Tried In Pitt, Varian Patent Fight
- Arent Fox Lures Patent Whiz From Merchant & Gould
- Abbott Lodges New Zemplar Patent Suit Against Hospira
- Diagnostics Co. Alere To Acquire EScreen For $270M
- Marine Polymer — Take 2
- Doctors Urge Hill To Get Rid Of Payment Advisory Board
- FDA Warnings Don't Always Start Limitations Clock: NJ Court
- Mandarin Capital Triples Investment In Italian Pharma Co.
- With Insider Trading On Upswing, FBI Turns To Gordon Gekko
- Buying Groups Shook Down Vaccine Customers, Sanofi Says
- Mylan Ends Calif. Drug Price Inflation Claims For $57M
- FDA Rejects Preterm Birth Drug From Watson, Columbia
- Glenmark Recalls Birth Control Over Faulty Packaging
- Shareholders Win Cert. In Suit Over Matrixx Cold Medicine
- The Changing Face Of US Health Care
- Where Is The Corporate Integrity Agreement?
- SNR Denton Boosts IP Group With 3 Buchanan Patent Experts
- Hypertension Drug's Labeling Problems Prompt GSK Recall
- Disease Groups Beg Congress For Antibiotics R&D Boost
- Nestle Likely In Lead To Buy Pfizer's $10B Baby Food Line
- Nixon Peabody Lands Ex-Pillsbury Gov't Contracts Pro
- Warner Chilcott Subpoenaed Over Marketing, Off-Label Use
- Debtholders Can't Get $40M From US Oncology For Now
- Crowell Adds Dorsey Commercial Litigation Pro In Calif.
- Varian Hit With $37M Verdict In Pitt Patent Suit
- Regulatory Demands To Spur Health M&A in 2012: Report
- House Bill Aims To Rein In State Drug, Device Inspections
- GSK, Teva Face Antitrust Class Action Over Lamictal Deal
- Texas Drug Fraud Law Preempted In J&J Suit: 5th Circ.
- Faulty Vials Prompt Blood Pressure Med Recall
- Mounting Pressure For FCPA Reform
- Wash.'s Contraceptive Sales Rules Unconstitutional: Judge
- 11th Circ. Revives $69M Fraud Suit Against Medco
- Pfizer Unit Scores More Time In Ch. 11 For Asbestos Dealings
- Genetic Disorder Patients Take Aim At US Over Drug Shortages
- J&J Tries To Ease EU Concerns Over $21B Synthes Deal
- A Few Lessons On Managing Product Recalls
- Insurer Aims To Duck Coverage Of Omeros FCA Suit
- 2nd Circ. Bars Trusts From $138M Biovail, Investors Deal
- 8 States Probe Abbott's Marketing Of Anti-Seizure Drug
- $1.7B Humira IP Verdict Won't Get Supreme Court Review
- CMS Sunshine Rule Will Unfairly Burden Docs: AMA, Others
- Forest's COPD Drug May Have Added Heart Risks: FDA
- Allergan, Others Sought Pinkeye Treatment Monopoly: Suit
- High Court Mulls Translator Bills For Lawsuit Losers
- Cellectis Hit With New Genome Engineering IP Suits
- Mylan Settles Defamation Suits Against Pittsburgh Paper
- FDA Calls For Voluntary Reporting Amid Drug Shortages
- Teva To Pay $270M In Propofol Hepatitis Suits
- Genomma Bids $834M For Prestige Brands
- Schering-Plough Strikes $12.5M Deal In ERISA Suit
- Omnicare Abandons $441M Offer To Buy PharMerica
- New Kaye Scholer Product Heads Aim To Expand Group's Reach
- Novartis Must Note Blood Pressure Drug Risks On EU Labels
- J&J Unit Recalls Infants' Tylenol Over Dosing Device
- Amgen Employees Press 9th Circ. To Revive ERISA Action
- PhRMA, Others Urge CMS To Back Off On Sunshine Rule
- Bristol-Myers Subpoenaed By DOJ For Abilify Info
- Swiss Regulator OKs Apax's $2B Mobile Co. Buyout
- Increasing Access To Innovative Biomedical Technology
- In Promotional Labeling, Size Matters
- Law School, Meet Litigation PR ...
- New Bill Would Give FDA Greater Development, Review Tools
- Jury Convicts 4 In $29M Medicaid Billing Scheme
- CVS Escapes Class Action Over Health Data Sales
- Shionogi Scuttled Deal By Destroying Fenoglide Pills: Suit
- USPTO Gene Test Fight Pits Patients Against Patents
- Sens. Demand Info From Ben Venue Over Drug Shortage
- Genzyme Recalls Leukemia Meds Over Factory Concerns
- Calif. High Court Takes Up Cipro Pay-For-Delay Suit
- Jury Awards Promega $52M In Genetic Test Kit IP Suit
- Volcker Rule Draws Fire From Range Of Nonbank Cos.
- Probe Into FDA Monitoring Of Whistleblower Emails Expands
- 3rd Circ. Trims Injunction In Stryker Employee Poaching Suit
- Ky. Court Shuts Down Class Cert. In Vioxx Fraud Action
- M&A Pro Jumps To Arnold & Porter From Allen & Overy
- GOP Signals Fight Ahead Over Medical Device User Fees
- NuVasive Can't Boot Patent After $101M Infringement Verdict
- Illumina Investors Claim Goldman Bias In Suit Over Roche Bid
- Colgate, Church & Dwight Settle Toothbrush-Package Suit
- Graceway Settles Claims With GTCR For $6M
- HHS, DOJ Recoup Record $4.1B From Health Fraud In FY 2011
- SAC Ramps Up Apple Stake To $433M In 4th Quarter
- Lawmakers Press FDA To Get Tough On Drug Trial Reporting
- Counterfeit Avastin Found In US, Roche Says
- Cell Therapeutics Settles Investor Lawsuit For $19M
- EDG Partners Closes 2nd Health Care Fund At $178M
- Genzyme, Insurer Settle Coverage Suit Over $64M Deal
- CMS Floats 60-Day Medicare Overpayment Refund Rule
- USPTO Patent Review Rules To Trigger Discovery Battles
- AlloDerm Insurer Sues Over Coverage For Alleged Injuries
- 'Independent Practice,' Collective Enforcement
- Omnicare Dodges Investor Action Over Kickback Claims
- Biogen To Spend $75M For Fibrosis Drug Co. Stromedix
- Insurer Wants Out Of J&J Supplier's Bug Infestation Suit
- Facebook, Others Weigh In On Fed. Circ. Intervening Rights Case
- Obama Budget Would Trim Health Entitlements By $350B
- Obama's 2013 Budget Targets Pay-For-Delay Deals
- Dental Device Maker Halts Operations Amid FDA Warnings
- Judge OKs 3 New Bellwethers In NuvaRing MDL
- Proskauer Fights To Dismiss J&J Heir's $140M Suit
- Drug Industry Balks At Obama's Budget Proposals
- Medtronic Pushes For Royalties In NuVasive Patent Row
- RI Hospital Puts Up $5M To End False Claims Allegations
- US, 4 States Join CVS Caremark Insurance Fraud Action
- Weil Gotshal Grabs Dechert Litigation Duo For NY Office
- Express Scripts, Medco Send FTC More Info On $29B Merger
- Examining Comcast's Calif. SBE Loss
- Shook Hardy Wields Largest Product Liability Group
- Mylan Must Shell Out $18M To Sunovion In Xopenex Patent Suit
- Delays Cost Cephalon TRO In Anti-Epilepsy Patent Suit
- Biosimilar Guidance Silent On Industry's Biggest Questions
- Merck, Bayer Target Watson Over Generic Beyaz Birth Control
- Baker Sports World's Biggest M&A Practice
- Mylan Escapes 6 Cases In Darvocet, Darvon MDL
- SNR Denton Leads Pack With Largest Privacy Group
- Latham & Watkins Dominates White Collar Arena
- DLA Piper Tops The List Of Megafirms
- US Sues Dallas Drug Compounder Over 3 Colchicine Deaths
- Pfizer Bests Investor Suit Over Alzheimer's Drug Trial
- Patient Wants High Court To Take Up Genzyme Negligence Suit
- Sens. Press OMB For Delayed Medical Device Rule
- FDA's Stepwise Approach To Demonstrating Biosimilarity
- Judge Misread Patent Claims, Sanofi Tells Fed. Circ.
- Jury Clears Sigma In $172M Medical Pump Patent Suit
- Case Study: Messner V. Northshore
- FDA Releases Guidance On Biosimilar Approvals At Last
- Ex-Leo Pharma Sales Reps Launch OT Class Action
- No Quick Appeal For Chinese Cos. In Vitamin C MDL
- Ex-Allergan President Escapes Investor Suit Over Exec Pay
- AstraZeneca Can't Block Generic Crestor: Fed. Circ.
- 9th Circ. Axes Lawsuit Over Stores' Drug Pricing Role
- Drug Cos. To Fund FDA Generics Reviews Under New Bill
- Catholic TV Network Sues US Over Birth Control Mandate
- Ex-Takeda Exec Settles SEC Insider Trading Claims
- Ex-Citigroup Exec Hits Abbott With Humira Cancer Suit
- No Quick Win For Ex-KV Pharma CEO On Criminal Costs
- How They Won It: Ropes & Gray Rescues Stryker Biotech
- FDA Panel Votes Against Amgen's Xgeva For Prostate Cancer
- Drug Co. Dava Pays $11M To End Medicaid Rebate Suit
- Ernst & Young Censured, Fined $2M Over Faulty Audits
- Mylan Can't Launch Doryx Generic Just Yet
- Popular Acid Reflux Drugs Can Trigger Infections: FDA
- Insurer Dodges Malpractice Liability Over Unfiled Suit
- 5th Circ. Frees Courts To Pick Fee Method In Class Deals
- FDA Faces Renewed Battle Over Plan B Age Restrictions
- Watson, J&J Settle Over Birth Control Generic
- Qui Tam Trends In 2011, Predictions For 2012
- 11th Circ. Won't Hear Venue Question In Denture MDL
- Illumina Board Urges Investors To Reject $6B Roche Bid
- Fed. Circ. Finds Exception To Late Interference Claims
- Bayer, Merial Flea Product Class Actions Merged In Ohio
- Hospitals Will Pay DOJ $12M To End Medicare Fraud Claims
- MDL Panel Sends Surgical Mesh Battles To W.Va.
- BioMed Realty Brings In Mass. Office Space For $119M
- Judge Upholds FDA Approval Of Generic Lovenox
- MoFo Adds Howard Hughes GC To Life Sciences Team
- DOL Tells High Court Drug Sales Reps Deserve OT Pay
- Class Actions And Causation: Duking It Out In 2012
- Pfizer Faces Antitrust Suit Over Generic Lipitor Delay
- Fed. Circ. Lifts Lupin Ban In Generic Fortamet Fight
- Wake Forest Blasts Jury Interrogatories In Fed. Circ. IP Case
- Ranbaxy Exits Pfizer's Suit Over Generic Rapamune
- Greenberg Adds Reed Smith Atty To Health Products Group
- RiverVest Investor Payouts Off $1B Sales Top Charts
- Mylan, Shire Battle Again Over Generic Vyvanse
- IRS Lays Out Plan For New Medical Device Tax
- Who's A Federal Contractor? You Just Might Be
- Smith & Nephew Pays $22M To Settle US Bribery Allegations
- BioSante Female Libido Drug Hype Was Fraudulent: Suit
- Cancer Drug Firm Duped Investors In $26M Offering: Suit
- Sen. Looks To Close Cost Gap In Hospitals' Implant Buys
- Pop Star Drake Sued By Ex-Girlfriend For Song Royalties
- Columbia Labs Sued Over Drug-Related Stock Drop
- GAO Scraps Protests Over $73M Medicare Auditing Contract
- Trends In M&A, Spin-Offs, Hostile Deals And PE
- Impax, Teva Put Generic-Wellbutrin MDL To Bed
- Senate Bill Would Streamline FDA's New Device Reviews
- 7th Circ. Shuts Down Abbott Workers' Benefit Appeal
- The Trouble With 'Confidential Witness' Allegations
- Sister Sledge Hammers Warner Over Download Royalties
- Highlighting 'Pay For Delay' Concerns
- A Little 'Guidance': All You Need For Preemption?
- EU Seeks Deeper Study Of Faulty Breast Implants
- States Need Guidelines When Hiring Outside Attys: Ex-AG
- Grassley Grills FDA Over Whistleblower Treatment
- Dentsply Blames Lewis & Roca For Contract Case Loss
- Sen. Blasts Express Scripts, Medco Deal On Antitrust Fears
- Angioblast Loses Contract Counterclaims Against UBS
- Ex-Reed Smith Life Sciences Pro Jumps To Hogan Lovells
- Bill Targets 'Loophole' In FDA Device Approval Process
- Witness Must Testify In Medtronic Off-Label Suit: Judge
- FCA Haul Topped $8.8B In Past 3 Years, Holder Says
- Kappos Says Prior Use Rule Shouldn't Be Changed For Now
- Astellas Can't Shake MDL Over Generic Prograf Delays
- House To Subpoena VA Docs Over Off-Contract Drug Buys
- 5th Circ. Allows State Claims In Stryker Implant Suit
- FDA Aims To Boost Inspections Of Foreign Drugmakers
- Pfizer Recalls Birth Control Pills After Packaging Mix-Up
- Mitigating Risk In Mass Nano Torts
- Push To Split Chairman, CEO Roles Gains Traction
- The Global Reach Of Stem Cell Research Patents
- Crowell Adds 3 Kilpatrick Townsend Drug IP Specialists
- SEC Panel Proposes Easing Regulation On Small Businesses